• Cyg0dxejdpobeum1u2mn

    Professor Ernst Wolvetang

Professor Wolvetang received his PhD in 1992 from the Department of Biochemistry, University of Amsterdam for his original work on peroxisomal disease (6 papers). He undertook postdoctoral studies at the Department of Biochemistry and the Institute for Reproduction and Development of Monash University, investigating apoptosis, Down syndrome and Ets transcription factors, respectively, obtaining the first evidence for an intra-chromosomal regulatory loop on chromosome 21 involving Ets2 (3 papers), and revealing the role of p53 in immune-suppression in Down syndrome (Hum Mol. Genetics). He then joined Professor Martin Pera in the Australian Stem Cell Centre in 2003 to pioneer human embryonic stem cell research in Australia, resulting in a first author Nature Biotechnology paper in 2006 identifying CD30 as a marker for genetically abnormal hESC (72 cites). He was appointed group leader of the basic human stem cell biology laboratory in the ASCC research laboratory and senior lecturer in the Department of Anatomy and Cell biology until he accepted his current position as an independent group leader at the AIBN and Professor in stem cell biology at the University of Queensland in 2008. There he started to generate integration-free induced pluripotent stem cells from human neurological diseases such as ataxia-telangiectasia (Stem cells translational medicine). In recognition of his leadership role in this area of research he was appointed leader of the “Reprogramming and Induction of pluripotency” Collaborative Stream of the Australian Stem Cell Centre until the end of that initiative in 2011, coordinating collaborative research between eight stem cell laboratories across Australia. He subsequently initiated and is now the president of Cell Reprogramming Australia, a collaborative framework aiming to facilitate and accelerate iPS cell research in Australia and the Asia pacific region and inform the general public about reprogramming technology. His research continues to combine cell reprogramming technology, genome editing/analysis tools and microfluidic/nanoparticle based detection/ delivery technologies with the aim of creating human in vitro models of disease, unravel the underlying gene regulatory networks and enable novel cell- and delivery-based therapeutics, respectively. He further co-direct the UQ-Centre for stem cell ageing and regenerative engineering (UQ-StemCARE).